Acumen Pharmaceuticals
ABOS
53 hedge funds and large institutions have $127M invested in Acumen Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 17 closing their positions.
172% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $611K
12% more capital invested
Capital invested by funds: $113M → $127M (+$13.9M)
3.48% less ownership
Funds ownership: 67.65% → 64.17% (-3.5%)
13% less funds holding
Funds holding: 61 → 53 (-8)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.39M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.91M |
| 3 |
CFP
Catalyst Financial Partners
Boston,
Massachusetts
|
+$429K |
| 4 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$359K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$300K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.23M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.73M |
| 3 |
CC
Commodore Capital
New York
|
-$1.62M |
| 4 |
BlackRock
New York
|
-$902K |
| 5 |
Walleye Capital
New York
|
-$798K |
ABOS Hedge Fund Activity: Q2 2023 in Review
53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q2 2023, worth a combined $127M — up 12% from $113M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ABOS and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $2.39M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $2.23M sold.
- 53 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $127M of Acumen Pharmaceuticals stock for Q2 2023, up 12% quarter-over-quarter.
- 9 funds opened new Acumen Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of -8 holders.
- The largest Acumen Pharmaceuticals buyer in Q2 2023 was Millennium Management, an estimated $2.39M added.
- The largest Acumen Pharmaceuticals seller in Q2 2023 was Driehaus Capital Management, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2023.